Coegin Pharma AB ("Coegin" or "the Company") provides a status update about the establishment of its own agile production facility in Denmark. It enables the Company to secure fulfillment of already received purchase orders, production capacity, quality control, and cost efficiency while supporting both commercial and R&D operations. Test production began in September, with initial commercial production of Follicopeptide® products starting in October 2025. 

Strengthening control, quality, and risk management 
With the new Danish facility, Coegin takes an important strategic step towards securing the Company's supply chain and fulfilling key milestones in the initial phase of the commercialization. By bringing production in-house, Coegin secures greater control over the entire manufacturing chain, from handling of raw materials, making finished products and ensuring that the science behind is validated with strict quality control.  

The decision not only enhances reliability and flexibility but also reduces dependency on external partners, mitigating both operational and financial risk. The facility is situated within a dynamic start-up and scale-up community in Denmark, also giving Coegin access to a vibrant ecosystem of expertise and collaboration opportunities. 

Jens Eriksson, CEO of Coegin Pharma, comments: 
"Establishing our own production facility is one of the most important strategic decisions we have made. It gives us full control of production timelines, quality, and costs - all crucial elements as we move from development to commercial scale. This setup ensures that we can deliver high-quality products on time while protecting margins and mitigating risks associated with outsourcing." 

The facility allows Coegin to manage both initial commercial production at scale and R&D activities, including optimization of production processes and development of new formulations. 

Commercial capacity and scalability at low cost 
The facility is designed to handle initial commercial-scale production with built-in scalability, allowing Coegin to increase output in line with market demand. Thanks to a well thought out setup of machinery, human resources, and premises, the company achieves a very cost-effective solution compared to outsourced production alternatives.  

Eriksson continues: 
"We have been able to establish a professional, flexible production setup at remarkably low cost. By leveraging smart, high-quality equipment and a skilled team, we combine efficiency with premium output, exactly what we need to support our growth ambitions."  

Dr. John Zibert, Chief Medical Officer at Coegin Pharma comments: 
"Having our own facility opens exciting possibilities for our R&D and production efforts. We can now optimize the Follicopeptide-gel production, develop new formulations, and advance our work on the pigmentation peptide NPP-4 all in one place. This integrated environment bridges the gap between innovation and production, allowing us to move faster, smarter, and at significantly lower cost."

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company developing cutting-edge innovations for hair and skin. The company is commercialising its first hair growth products  in late 2025, followed by a pigmentation product in 2026.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

Attached files